Collegium Pharmaceutical
COLL
193 hedge funds and large institutions have $1.24B invested in Collegium Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 58 increasing their positions, 77 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
43% more capital invested
Capital invested by funds: $865M → $1.24B (+$373M)
12.06% more ownership
Funds ownership: 111.28% → 123.34% (+12%)
11% more funds holding
Funds holding: 174 → 193 (+19)
25% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 77
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
86% less call options, than puts
Call options by funds: $305K | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$35.4M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$22.1M |
| 3 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$7.91M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.06M |
| 5 |
Renaissance Technologies
New York
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$11.4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$10.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.33M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.27M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.29M |
COLL Hedge Fund Activity: Q4 2023 in Review
193 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2023, worth a combined $1.24B — up 43% from $865M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new COLL positions and 13 closed out — a net gain of 20 holders — while 58 added to existing stakes and 77 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $35.4M. The largest seller was BlackRock, cutting an estimated $11.4M.
- 193 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2023, up from 174 in Q3 2023.
- Funds reported $1.24B of Collegium Pharmaceutical stock for Q4 2023, up 43% quarter-over-quarter.
- 33 funds opened new Collegium Pharmaceutical positions in Q4 2023 and 13 closed out, a net change of +20 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2023 was Morgan Stanley, an estimated $35.4M added.
- The largest Collegium Pharmaceutical seller in Q4 2023 was BlackRock, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2023.